Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: Case report and review of the literature

Archives of Dermatology

Volumn 147, Issue 12, 2011, Pages 1418-1423

  Hoesly, Fridolin J ^a   Baker, Sarah G ^a   Gunawardane, Nilanthi D ^a   Cotliar, Jonathan A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; ANTIBIOTIC AGENT; CAPECITABINE; CIPROFLOXACIN; ECONAZOLE; FLUOCINONIDE; LAPATINIB; PSEUDOMONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SUPERINFECTION; BLOOD CLOTTING DISORDER; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; DEATH; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EMERGENCY WARD; ERYTHEMA; EYE JAUNDICE; FATALITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEG SWELLING; LIVER DYSFUNCTION; MALAISE; MEDICAL HISTORY; METASTASIS POTENTIAL; PAIN; PARONYCHIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESUSCITATION; SEPSIS; SEPTIC SHOCK; SKIN CULTURE; SKIN DISEASE; SKIN EROSION; SKIN ULCER; TREATMENT DURATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BACTEREMIA; BREAST NEOPLASMS; DEOXYCYTIDINE; FATAL OUTCOME; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PSEUDOMONAS INFECTIONS; SUPERINFECTION;

EID: 84255171370     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.320     Document Type: Article

References (38)

1. Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome - a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol. 2006;16(5):494-499. (Pubitemid 44861822)
2. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257-271.
3. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524-529.
4. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ("hand-foot") syndrome: incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-234.
5. Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Ther. 2004; 1(4):213-218.
6. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001-1011.
7. Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxelcapecitabine therapy is treated with vitamin E without dose reduction. Breast. 2006;15(3):414-424.
8. Guenova E, Weber HO, Voykov B, et al. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Arch Dermatol. 2008;144(8):1081-1082.
9. Palaia I, Angioli R, Bellati F, Basile S, Rabitti C, Panici PB. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia. Am J Obstet Gynecol. 2006;195(4):e1-e2. (Pubitemid 44415648)
10. Han JY, Lee DH, Kim HY, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer. 2003; 98(9):1918-1924. (Pubitemid 37310235)
11. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute Web site. http://ctep.cancer.gov/protocolDevelopment/electronic -applications/ctc.htm. Accessed April 22, 2011.
12. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131-141. (Pubitemid 44696441)
13. Heo YS, Chang HM, Kim TW, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol. 2004; 44(10):1166-1172. (Pubitemid 39202461)
14. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114 (3):485-493.
15. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955-1961.
16. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995;75(8):2169-2173.
17. Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist. 2007;12(10):1178-1182. (Pubitemid 350106348)
18. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009; 60(2):299-305.
19. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886-892. (Pubitemid 352039741)
20. Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005; 16(7):1210-1211. (Pubitemid 41418329)
21. Milano G, Etienne-Grimaldi MC, Mari M, et al. Candidate mechanisms for capecitabinerelated hand-foot syndrome. Br J Clin Pharmacol. 2008;66(1):88-95. (Pubitemid 351822156)
22. Chu D, Lacouture ME, Fillos T,WuS. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176-186.
23. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011;10 (2):159-169.
24. Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008;108(2):332-335.
25. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002;49(3):225-234. (Pubitemid 34185596)
26. Chin SF, Tchen N, Oza AM, Moore MJ, Warr D, Siu LL. Use of "Bag Balm" as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents [abstract 1632]. Proc Am Soc Clin Oncol. 2001;20:409a.
27. Pendharkar D, Goyal H. Novel and effective management of capecitabine induced hand foot syndrome. J Clin Oncol. 2004;22(14S):8105.
28. Yoshimoto N, Yamashita T, Fujita T, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer. 2010;17(4):298-302.
29. Beveridge RA, Kales AN, Binder RA, Miller JA, Virts SG. Pyridoxine (B6) and amelioration of hand/foot syndrome [abstract 393]. Proc Am Soc Clin Oncol. 1990; 9:102a.
30. Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol. 1990; 26(6):449-452. (Pubitemid 20333750)
31. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8(1):57-63. (Pubitemid 20087245)
32. Mortimer J, Lauman MJ, Tan B, Dempsey CL, Shillington AC, Hutchins KS. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract. 2003;9(4):161-166. (Pubitemid 37461547)
33. Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine- associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol. 2010;6(3):155-160.
34. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced handfoot syndrome and antitumor activity. Oncology (Williston Park). 2002;16(12) (suppl 14):31-37.
35. Kingsley EC. 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med. 1994;120(9):813. (Pubitemid 24125309)
36. Somerfield M, Padberg J, Pfister D, et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Curr Comments. 2000; 4:881-886.
37. Wolf SL, Qin R, Menon SP, et al.; North Central Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced handfoot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28(35):5182-5187.
38. Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent handfoot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824- 3829.